The first-generation cephalosporin antibiotic Cephradine (Ultracef) is commonly used to help manage infections caused by susceptible bacteria, relevant for easing symptoms related to inflammatory or irritative states. This class of medication is primarily relevant for infections affecting several key systems.

---

Therapeutic Scope and Benefits

Ultracef is frequently applied across domains where supportive symptom management is appropriate for infections of the Respiratory Tract (e.g., tonsillitis, bronchitis), otitis media, Skin and Soft Tissue (e.g., cellulitis, abscesses), and the Urinary Tract (e.g., cystitis, pyelonephritis). The medication plays a role in managing conditions presenting with symptoms that interfere with daily comfort, such as fever, localized pain, and painful urination (dysuria). In acute scenarios, this generally supports the patient during difficult episodes by easing distress associated with localized inflammation and systemic imbalance. Furthermore, it is considered relevant as surgical prophylaxis when appropriate to manage the risk of post-operative bacterial contamination.

“It is relevant for managing symptoms that interfere with daily comfort.”

---

Quick Fact: Supports Easing of Localized Pain and Fever

Brief Listing of Indications

Ultracef is commonly used to help manage acute symptomatic episodes, particularly Respiratory Tract Infections including pharyngitis and tonsillitis; Skin and Soft Tissue Infections such as cellulitis and abscesses; and Urinary Tract Infections, which can manifest as cystitis or pyelonephritis.

Regulatory References

1. National Center for Biotechnology Information (NCBI) review

Who Can and Cannot Use Ultracef?

The eligibility for using Ultracef (Cephradine) is strictly defined by official regulatory labeling, focusing on patient hypersensitivity, age, and organ function. The drug is classified for use only under specific population-based constraints.

Eligibility Scope

Category	Regulatory Status
Populations for whom use is contraindicated	Patients with a known hypersensitivity to Cephradine or to any antibiotic in the cephalosporin class are absolutely prohibited from use.
Age-related eligibility rules	Use is established for adults and for pediatric patients who are 9 months of age and older. Safety and efficacy are not established for infants under 9 months.
Condition-specific eligibility rules	Patients with impaired renal function must be treated with caution and require mandatory dosage adjustment to prevent drug accumulation. The drug requires great caution in patients with a history of penicillin allergy or colitis due to potential cross-sensitivity and gastrointestinal risks.
Pregnancy and lactation eligibility status	Pregnancy: The drug is classified as Category B; use is generally avoided unless clearly essential. Lactation: Use requires caution as the drug is known to be excreted into human milk.

---

Eligibility Classifications (High-Level)

The primary regulatory constraint is the Absolute Hypersensitivity Contraindication. Conditional eligibility, defined by Organ Function and Allergy History constraints, requires caution, clinical observation, and/or dosage modification.

Interactions with other medicines and products

The regulatory profile for Cephradine (Ultracef) is structured around substances that alter its exposure or contribute to additive adverse effects. No combinations are universally classified as contraindicated in available official regulatory documents.

---

Interaction Scope

Property	Statement
Medicinal product categories with documented interactions	Renal tubular blocking agents; Loop Diuretics; Hormonal contraceptives; Mineral supplements.
Specific interacting medicines (if explicitly listed)	Probenecid; Furosemide; Oral products containing Zinc.
Timing-based interaction rules (if applicable)	Oral Cephradine and oral products containing Zinc must be administered at least three hours apart to mitigate reduced Cephradine absorption.

---

Official Interaction Statements

• Co-administration of Probenecid reduces the renal clearance of Cephradine, leading to raised and prolonged serum concentrations (increased systemic exposure) as a result of competitive inhibition of renal tubular secretion.
• Concurrent use with Loop Diuretics (such as Furosemide) may increase the risk of nephrotoxicity, which is a documented pharmacodynamic interaction reflecting additive organ toxicity.
• Oral administration of Zinc-containing products interferes with the absorption of Cephradine from the gastrointestinal tract, diminishing systemic exposure, which requires timing separation.
• Use of Cephradine may reduce the effectiveness of hormonal oral contraceptives by interfering with the circulation of the hormones.

---

The interaction profile is defined by pharmacokinetic modifications, such as the increase in exposure by Probenecid and the potential decrease in exposure caused by mineral supplements like zinc, alongside the additive risk of organ toxicity associated with co-administration of Loop Diuretics.

Inhibition of Bacterial Cell Wall Synthesis

Ultracef exerts its action by functioning as a beta-lactam inhibitor, primarily targeting the bacterial Penicillin-Binding Proteins (PBPs), which are transpeptidases essential for cell wall construction. The drug acts by covalently and irreversibly binding to the active site of these enzymes, preventing their normal function. This specific interaction blocks the final transpeptidation step necessary for cross-linking peptidoglycan polymers, which are the fundamental structural components of the bacterial cell wall.

---

Impairment of Osmotic Stability and Lysis

Modification of the peptidoglycan synthesis cascade results in a deficiency in the formation of a rigid, stable cell wall structure. This structural impairment prevents the bacterial cell from adequately counteracting its high internal osmotic pressure. The physiological consequence of this is the triggering of bacterial autolytic processes and rapid cell lysis, a mechanism that ultimately governs the effect profile of the drug.

How Ultracef (Cephradine) is Used

The administration of Ultracef (Cephradine) is governed by specific guidelines to ensure proper use, based on its availability in multiple forms and routes. This section details the standardized instructions for its delivery, dosing, and scheduling as outlined in prescribing information, excluding all safety and efficacy details.

---

Approved Administration and Dosage Forms

Cephradine is approved for use via two primary methods:

• Oral Administration: Available as capsules (250 mg and 500 mg) and as an oral suspension (125 mg/5 mL and 250 mg/5 mL). Oral forms may be taken without regard to meals.
• Parenteral Administration: Available as a powder for solution (500 mg and 1 g vials) for preparation of Intramuscular (IM) injection or Intravenous (IV) injection/infusion.

---

Standard Dosing and Scheduling

The standard adult oral dosage for susceptible infections is typically 250 mg to 500 mg every 6 hours (Q6H) or 500 mg to 1 g every 12 hours (Q12H). For severe infections, the dose may increase up to 1 g four times daily. Parenteral treatment doses usually range from 2 g to 4 g total daily, administered in four equal doses (Q6H). The maximum daily dose for parenteral use is 8 g.

---

Essential Administration Requirements

Requirement	Official Instruction
Preparation	Oral suspension and powder for injection require reconstitution according to specific label directions.
IV Injection	Intravenous doses should be administered slowly, typically over 3 to 5 minutes, or by infusion.
Duration	Treatment should continue for a minimum of 2 to 3 days after signs of infection have resolved.
Dose Adjustment	Mandatory dose modification is required for patients with impaired renal function based on measured Creatinine Clearance (CrCl).
Pediatrics	Pediatric dosing is based on body weight, typically 25 mg/kg/day to 50 mg/kg/day total, divided into equal Q6H or Q12H doses.

Research evidence / Overview of Studies for Ultracef (Cephradine)

Evidence for use in Urinary Tract Infections (UTI)

Research has explored the use of Ultracef (Cephradine) for conditions associated with acute or disruptive episodes, such as urinary tract infections (UTIs). Studies focusing on episodes where symptoms become more noticeable include short-term comparative randomized controlled trials (RCTs). These trials were designed to monitor outcomes related to systemic or functional imbalance, including measurements of the specific bacteria's presence or absence, and assessing patient-reported outcomes describing perceived discomfort, such as the observation of symptom changes, including painful urination (dysuria). The research examined both adult patients experiencing uncomplicated UTIs and those with more chronic or complicated infections. Findings describe patterns observed in the studies where measurements of bacterial status were reported, with data existing from trials involving acute, uncomplicated infection. Comparative trials sometimes reported measured outcomes when the drug was observed in comparison to other antibacterial agents of the time.

Evidence for use in Skin and Soft Tissue Infections (SSTI)

Ultracef was evaluated in studies for skin and soft tissue infections (SSTIs). Research for SSTIs includes controlled double-blind studies and comparative trials. The studies explored short-term symptom changes by monitoring outcomes related to physical discomfort, such as the assessment of changes in infection signs, and microbiological outcomes related to the status of susceptible pathogens like Staphylococcus aureus. The available research highlights changes measured during the study period, describing patterns of clinical change and pathogen status for patients with less complicated infections.

Evidence for use in Respiratory Tract Infections (RTI)

Research has examined the use of Ultracef for various respiratory tract infections (RTIs). The evidence base includes comparative clinical trials. Studies monitored outcomes related to physical discomfort, such as changes in cough and fever, as well as the status of the bacterial pathogen. Comparative trials exploring measurements of clinical response and bacteriological outcome when Cephradine was compared to other established antibiotics used in the research were reported.

What is Still Uncertain About Ultracef Research

Research exploring short-term symptom changes is the predominant focus of the available evidence. Follow-up durations were limited in most trials, and there is limited information for extended outcomes related to the pattern of symptom recurrence. Long-term effects are not established due to limited follow-up durations in the research. Many of the core studies were conducted some time ago, and the findings may have limitations in providing context for contemporary patterns of bacterial resistance. Furthermore, sample sizes were modest in several original trials, and comparative evidence against more recently developed treatments is often lacking. The overall research quality varies across studies, suggesting certainty remains low in certain areas, and more modern investigation is needed to address these limitations.

Key Studies & References

1. Cefradine (Monograph, including indications for RTI, SSTI, UTI, and special populations)
2. Cefradine (DrugBank Monograph covering indications, mechanism, and general pharmacokinetics)

Common questions about Ultracef (FAQ)

Q: How long does it take for Ultracef to start working?

Ultracef typically begins to lower cholesterol levels within two weeks of starting treatment, with the maximal therapeutic effect generally observed after four to six weeks. The best results are typically observed when the medication is taken daily as prescribed. Discontinuing the medication should only be done under a healthcare provider's direction, as cholesterol levels may rise after treatment is stopped.

Q: Can I drink alcohol while taking Ultracef?

Official prescribing information advises caution or limiting alcohol consumption while taking Ultracef, as excessive alcohol intake may increase the risk of liver-related side effects, which is a known concern with statin medications. A healthcare provider is the best source of guidance regarding alcohol intake and liver health while on this medication.

Q: What should I do if I miss a dose of Ultracef?

Specific instructions for a missed dose are outlined in the patient information leaflet and should always be confirmed by your healthcare provider. Generally, if a dose is missed, it should be taken as soon as possible unless it is nearly time for the next scheduled dose. Patients are generally advised not to take two doses at the same time to make up for a missed dose. If doses are missed frequently, it is important to discuss this with a healthcare provider to review the treatment plan.

Q: Is Ultracef safe for everyone?

Ultracef is generally considered safe when taken as prescribed, but it is not suitable for everyone. The medication is contraindicated for women who are pregnant or breastfeeding. In some clinical situations, Ultracef may be preferred over other statins; however, a doctor must evaluate its suitability based on the patient's full health history, especially for those with pre-existing liver conditions.

Ultracef (Cephradine) storage and disposal requirements are dictated by regulatory standards to ensure product quality.

Storage and Stability

Product Form	Temperature Constraint	Stability After Reconstitution
Capsules / Dry Powder	Store at a cool, dry room temperature, not exceeding 30 C	Not applicable
Oral Suspension	Store reconstituted suspension for 14 days under refrigeration (2 C to 8 C), or 7 days at room temperature (not exceeding 30 C)	Limited (7 or 14 days)
Injection Solution	Use within a short, specified period (e.g., 2 to 12 hours) depending on temperature/diluent	Limited (hours)

All forms must be kept in the original, tightly closed container and protected from moisture and light. Storage environments must avoid excessive heat. The product must always be kept out of the reach and sight of children.

Disposal Requirements

Unused or expired Ultracef must be disposed of according to local regulations to prevent environmental contamination. Patients should utilize a recognized pharmacy take-back program where available. The product must not be discarded into water courses or drains.